Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.

Li PK, Kwan BC, Chow KM, Leung CB, Szeto CC.

Am J Med. 2013 Feb;126(2):162-8. doi: 10.1016/j.amjmed.2012.06.028.

PMID:
23331443
2.

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

Manno C, Torres DD, Rossini M, Pesce F, Schena FP.

Nephrol Dial Transplant. 2009 Dec;24(12):3694-701. doi: 10.1093/ndt/gfp356. Epub 2009 Jul 23. Erratum in: Nephrol Dial Transplant. 2010 Apr;25(4):1363-4.

PMID:
19628647
3.

Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.

Cruzado JM, Poveda R, Ibernón M, Díaz M, Fulladosa X, Carrera M, Torras J, Bestard O, Navarro I, Ballarín J, Romero R, Grinyó JM.

Nephrol Dial Transplant. 2011 Nov;26(11):3596-602. doi: 10.1093/ndt/gfr072. Epub 2011 Mar 10.

PMID:
21393611
4.

Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.

Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.

Hypertens Res. 2004 Dec;27(12):963-70.

5.
6.

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G.

Am J Kidney Dis. 2000 Jun;35(6):1155-65.

PMID:
10845831
7.

Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.

Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.

Clin Exp Nephrol. 2011 Oct;15(5):700-7. doi: 10.1007/s10157-011-0455-8. Epub 2011 May 31.

PMID:
21625892
8.

Can young adult patients with proteinuric IgA nephropathy perform physical exercise?

Fuiano G, Mancuso D, Cianfrone P, Comi N, Mazza G, Marino F, Fuiano L, Zamboli P, Caglioti A, Andreucci M.

Am J Kidney Dis. 2004 Aug;44(2):257-63.

PMID:
15264183
9.

Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.

Moriyama T, Nakayama K, Ochi A, Amemiya N, Tsuruta Y, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.

Clin Exp Nephrol. 2012 Apr;16(2):231-7. doi: 10.1007/s10157-011-0545-7. Epub 2011 Oct 26.

PMID:
22038185
10.

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.

Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC; HKVIN Study Group.

Am J Kidney Dis. 2006 May;47(5):751-60.

PMID:
16632013
12.

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.

Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G.

Lancet. 1999 Jul 31;354(9176):359-64.

PMID:
10437863
13.

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL.

Arch Intern Med. 2005 Apr 25;165(8):947-53.

PMID:
15851648
14.

[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].

Erley CM, Berger ED, Heyne N, Klass M, Krämer D, Braun N, Wolf S, Risler T.

Dtsch Med Wochenschr. 1997 Aug 1;122(31-32):953-8. German.

PMID:
9280714
15.

ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.

Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia.

J Am Soc Nephrol. 2001 Dec;12(12):2832-7.

16.
17.

Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.

Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.

Transplant Proc. 2011 Jul-Aug;43(6):2187-90. doi: 10.1016/j.transproceed.2011.06.055.

PMID:
21839229
18.

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.

Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD.

Nephrol Dial Transplant. 2008 Feb;23(2):573-9. Epub 2007 Nov 4.

PMID:
17984104
19.

The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.

Draman CR, Kong NC, Gafor AH, Rahman AF, Zainuddin S, Mustaffa WM, Radzi AM, Shamsul AS.

Singapore Med J. 2008 Nov;49(11):924-9.

Supplemental Content

Support Center